Search research articles
Contact Us
Filters
Showing results (281-290 of 290) with videos related to
Page
of 29
Sort By:
You have reached the last page of results.
This site can display upto 290 results.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
November 22, 2007
Increased utilization of peritoneal dialysis to cope with mounting demand for renal replacement therapy--perspectives from Asian countries
Philip Kam-Tao Li, Sing Leung Lui, Chi Bon Leung, et al.
Actas Dermo-Sifiliograficas
|
March 5, 2025
Acral Melanoma in the Caucasian Population: A Comprehensive Cohort Study on Epidemiological, Clinicopathological, and Prognostic Features
J Angel-Baldo, S Podlipnik, A Azón, et al.
Actas Dermo-Sifiliograficas
|
January 11, 2025
Acral Melanoma in the Caucasian Population: A Comprehensive Cohort Study on Epidemiological, Clinicopathological, and Prognostic Features
J Angel-Baldo, S Podlipnik, A Azón, et al.
Actas Dermo-Sifiliograficas
|
March 13, 2010
[Initial evaluation, diagnosis, staging, treatment, and follow-up of patients with primary cutaneous malignant melanoma. Consensus statement of the Network of Catalan and Balearic Melanoma Centers]
C Mangas, C Paradelo, S Puig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
M Graeser, O Gluz, C Zu Eulenburg, et al.
ESMO Open
|
August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)
O Gluz, U Nitz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
G von Minckwitz, S Loibl, M Untch, et al.
Page
of 29
Search research articles
Search
Showing results (281-290 of 290) with videos related to
Sort By:
Page
of 29
You have reached the last page of results.
This site can display upto 290 results.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
November 22, 2007
Increased utilization of peritoneal dialysis to cope with mounting demand for renal replacement therapy--perspectives from Asian countries
Philip Kam-Tao Li, Sing Leung Lui, Chi Bon Leung, et al.
Actas Dermo-Sifiliograficas
|
March 5, 2025
Acral Melanoma in the Caucasian Population: A Comprehensive Cohort Study on Epidemiological, Clinicopathological, and Prognostic Features
J Angel-Baldo, S Podlipnik, A Azón, et al.
Actas Dermo-Sifiliograficas
|
January 11, 2025
Acral Melanoma in the Caucasian Population: A Comprehensive Cohort Study on Epidemiological, Clinicopathological, and Prognostic Features
J Angel-Baldo, S Podlipnik, A Azón, et al.
Actas Dermo-Sifiliograficas
|
March 13, 2010
[Initial evaluation, diagnosis, staging, treatment, and follow-up of patients with primary cutaneous malignant melanoma. Consensus statement of the Network of Catalan and Balearic Melanoma Centers]
C Mangas, C Paradelo, S Puig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
M Graeser, O Gluz, C Zu Eulenburg, et al.
ESMO Open
|
August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)
O Gluz, U Nitz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
G von Minckwitz, S Loibl, M Untch, et al.
Page
of 29